Log in

6660 AIM Vaccine Co., Ltd. HKEX · China

AIM Vaccine Co. (6660) news

AIM Vaccine Co., Ltd. is a public biotech or pharmaceutical company listed on HKEX under the ticker 6660, recorded under China. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest AIM Vaccine Co. news

We have not published a story on AIM Vaccine Co. yet. When there is news, it will appear here.

Questions about AIM Vaccine Co.

What is the ticker symbol of AIM Vaccine Co.?

AIM Vaccine Co., Ltd. trades under the ticker 6660 on HKEX.

Where is AIM Vaccine Co. listed?

AIM Vaccine Co., Ltd. is listed on HKEX.

Which country or territory is AIM Vaccine Co. listed under?

Our directory records AIM Vaccine Co., Ltd. under China.

What does AIM Vaccine Co. do?

Our directory classifies AIM Vaccine Co., Ltd. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of AIM Vaccine Co.?

The ISIN recorded for AIM Vaccine Co., Ltd. is CNE100005KF2.

Does aibio.space cover AIM Vaccine Co.?

aibio.space lists AIM Vaccine Co., Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to AIM Vaccine Co.?

Companies in our directory listed in the same country and business area as AIM Vaccine Co.: Shanghai Obio Technology (Group) Corp., Hangzhou Tigermed Consulting Co., Hvsen Biotechnology Co., Kintor Pharmaceutical, Liaoning Chengda Biotechnology Co., Getein Biotech.

Investor discussion: AIM Vaccine Co.

Members talk about AIM Vaccine Co. (6660). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at AIM Vaccine Co., newest first. Each line links the filing it comes from.

  1. Financings

    Share or debt issue: (1) PROPOSED AMENDMENTS TO THE ISSUANCE OF DOMESTIC UNLISTED SHARES UNDER SPECIFIC MANDATE, CONNECTED TRANSACTION IN RESPECT OF THE PROPOSED ISSUANCE OF DOMESTIC UNLISTED SHARES AND SUBSCRIPTION IN RESPECT OF THE PROPOSED ISSUANCE OF DOMESTIC UNLISTED SHARES; AND (2) NOTICE OF THE 2026 SECOND EXTRAORDINARY GENERAL MEETING. Source

  2. Financings

    Share or debt issue: (1) PROPOSED AMENDMENTS TO THE ISSUANCE OF DOMESTIC UNLISTED SHARES UNDER SPECIFIC MANDATE; (2) CONNECTED TRANSACTION IN RESPECT OF THE PROPOSED ISSUANCE OF DOMESTIC UNLISTED SHARES; AND (3) SUBSCRIPTION IN RESPECT OF THE PROPOSED ISSUANCE OF DOMESTIC UNLISTED SHARES. Source

  3. Financings

    Share or debt issue: PROPOSED APPLICATION BY THE COMPANY FOR THE A SHARE LISTING ON THE BEIJING STOCK EXCHANGE AND ISSUANCE OF DOMESTIC SHARES UNDER SPECIFIC MANDATE. Source

  4. Financings

    Share or debt issue: CIRCULAR OF 2025 ANNUAL GENERAL MEETING. Source

  5. Financings

    Share or debt issue: INSIDE INFORMATION PROPOSED APPLICATION BY THE COMPANY FOR THE A SHARE LISTING ON THE BEIJING STOCK EXCHANGE AND ISSUANCE OF DOMESTIC SHARES UNDER SPECIFIC MANDATE. Source

  6. Financings

    Share or debt issue: CIRCULAR OF 2024 ANNUAL GENERAL MEETING. Source

  7. Financings

    Share or debt issue: PLACING OF NEW H SHARES UNDER GENERAL MANDATE. Source

Press releases

Headlines of AIM Vaccine Co.'s own announcements, newest first. Each opens the full release on the newswire that carried it.

  1. HKEXnews

    ADJOURNMENT OF EXTRAORDINARY GENERAL MEETING AND CHANGE OF BOOK CLOSURE PERIOD

  2. HKEXnews

    VOLUNTARY ANNOUNCEMENT SUBMISSION OF THE APPLICATION FOR MARKETING REGISTRATION OF THE ITERATIVE PROCESS HIGH-POTENCY HUMAN DIPLOID CELL RABIES VACCINE

  3. HKEXnews

    INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026

  4. HKEXnews

    Documents on Display

  5. HKEXnews

    NOTICE OF THE 2026 SECOND EXTRAORDINARY GENERAL MEETING

  6. HKEXnews

    (1) PROPOSED AMENDMENTS TO THE ISSUANCE OF DOMESTIC UNLISTED SHARES UNDER SPECIFIC MANDATE, CONNECTED TRANSACTION IN RESPECT OF THE PROPOSED ISSUANCE OF DOMESTIC UNLISTED SHARES AND SUBSCRIPTION IN RESPECT OF THE PROPOSED ISSUANCE OF DOMESTIC UNLISTED SHARES; AND (2) NOTICE OF THE 2026 SECOND EXTRAORDINARY GENERAL MEETING

  7. HKEXnews

    (1) PROPOSED AMENDMENTS TO THE ISSUANCE OF DOMESTIC UNLISTED SHARES UNDER SPECIFIC MANDATE; (2) CONNECTED TRANSACTION IN RESPECT OF THE PROPOSED ISSUANCE OF DOMESTIC UNLISTED SHARES; AND (3) SUBSCRIPTION IN RESPECT OF THE PROPOSED ISSUANCE OF DOMESTIC UNLISTED SHARES

  8. HKEXnews

    VOLUNTARY ANNOUNCEMENT COMPLETION OF SUBMISSION OF SUPPLEMENTARY DATA FOR MARKET REGISTRATION OF SERUM-FREE ITERATIVE RABIES VACCINE REGISTRATION APPLICATION ACHIEVES IMPORTANT PROGRESS

  9. HKEXnews

    (1) POLL RESULTS OF THE 2026 FIRST EXTRAORDINARY GENERAL MEETING HELD ON JUNE 10, 2026; AND (2) AMENDMENTS TO THE ARTICLES OF ASSOCIATION

  10. HKEXnews

    Articles of Association

  11. HKEXnews

    (1) POLL RESULTS OF THE 2025 ANNUAL GENERAL MEETING HELD ON JUNE 10, 2026; (2) AMENDMENTS TO THE ARTICLES OF ASSOCIATION; (3) RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND APPOINTMENT OF DIRECTORS; (4) APPOINTMENT OF EXECUTIVE PRESIDENT; AND (5) CHANGE IN COMPOSITION OF BOARD COMMITTEES

  12. HKEXnews

    SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025

  13. HKEXnews

    NOTICE OF THE 2026 FIRST EXTRAORDINARY GENERAL MEETING

  14. HKEXnews

    PROPOSED APPLICATION BY THE COMPANY FOR THE A SHARE LISTING ON THE BEIJING STOCK EXCHANGE AND ISSUANCE OF DOMESTIC SHARES UNDER SPECIFIC MANDATE

  15. HKEXnews

    NOTICE OF 2025 ANNUAL GENERAL MEETING

  16. HKEXnews

    CIRCULAR OF 2025 ANNUAL GENERAL MEETING

  17. HKEXnews

    (1) RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND PROPOSED ELECTION OF DIRECTORS; AND (2) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND RULES OF PROCEDURES OF THE BOARD OF DIRECTORS

  18. HKEXnews

    INSIDE INFORMATION PROPOSED APPLICATION BY THE COMPANY FOR THE A SHARE LISTING ON THE BEIJING STOCK EXCHANGE AND ISSUANCE OF DOMESTIC SHARES UNDER SPECIFIC MANDATE

  19. HKEXnews

    ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025

  20. HKEXnews

    VOLUNTARY ANNOUNCEMENT WORLD'S FIRST SERUM-FREE ITERATIVE RABIES VACCINE SUCCESSFULLY PASSED ON-SITE INSPECTION FOR REGISTRATION

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:6660 on TradingView.

Listing details

AIM Vaccine Co., Ltd. is a public biotech or pharmaceutical company listed on HKEX under the ticker 6660, recorded under China. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
AIM Vaccine Co., Ltd.
Ticker
6660
Listing
HKEX
Country or territory
China
Business scope
Biotechnology
ISIN
CNE100005KF2
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.